Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma | BMC Cancer | Full Text

Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma | BMC Cancer | Full Text

Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma

Although checkpoint blockades have become widely used, the immunological impact in cancer patients, especially those with oral cavity squamous cell carcinoma (OCSCC), has not been well studied.

Authors:Ying Xiong, David M. Neskey, Joshua D. Horton, Chrystal M. Paulos, Hannah M. Knochelmann, Kent E. Armeson and M. Rita I. Young

Citation:BMC Cancer 2020 20:229

Content type:Research article

Published on: 17 March 2020

• ViewFull Text
 
• ViewPDF